Compare GSUN & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSUN | MBAI |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 10.1M |
| IPO Year | 2022 | N/A |
| Metric | GSUN | MBAI |
|---|---|---|
| Price | $1.30 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.9K | 37.8K |
| Earning Date | 02-12-2026 | 02-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,314,724.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 526.22 | N/A |
| 52 Week Low | $0.98 | $0.59 |
| 52 Week High | $5.25 | $3.13 |
| Indicator | GSUN | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | N/A |
| Support Level | $1.12 | N/A |
| Resistance Level | $1.22 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 90.32 | 0.00 |
Golden Sun Health Technology Group Ltd is a holding company. Along with its subsidiaries, it is engaged in the provision of education services and e-commerce business in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistics and consulting services. It has also established its wellness brands and an e-commerce platform to promote and sell wellness products. The company operates in the following segments; Education, which generates maximum revenue, and E-commerce.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.